HONG KONG and SAN FRANCISCO, Jan. 6, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“It’s coming” or the “Company”) is pleased to announce their participation in the upcoming 43rd Annual JP Morgan Healthcare Conferencewhich happened in January 13, 2025on San Francisco, California. The company’s founder, chairwoman, president, and CEO, Dr. Michelle Xia share the latest developments and plans for its globally leading programs, including ivonescimab (PD-1/VEGF bispecific antibody), cadonilimab (PD-1/CTLA-4 bispecific antibody), and ligufalimab (CD47 monoclonal antibody), as well as other cutting-edge multispecific antibody pipeline assets.

timeSF local time 2:15-2:55pm, Jan. 15, 2025

About It’s coming

It’s coming (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of first-in-class or best-in-class novel biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system. and a commercialization system with an advanced mode of operation, and is gradually becoming a globally competitive biopharmaceutical company focused on innovative solutions. With a fully integrated multi-functional platform, It’s coming working within a robust pipeline of over 50 new properties in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). In addition, 5 new drugs are commercially available, and 5 new drugs in 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, It’s coming constantly combines the world’s best resources, develops first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients around the world, and continues to create added commercial and social values ​​to become a global leading biopharmaceutical business.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on LinkedInand X.